Cargando…

Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2′-Fucosyllactose

Human milk oligosaccharides (HMOs) are the third most abundant solid component in human milk after lactose and lipids. Preclinical research has demonstrated that HMOs and specifically 2′-fucosyllactose (2′-FL) are more than a prebiotic and have multiple functions, including immune, gut, and cognitio...

Descripción completa

Detalles Bibliográficos
Autores principales: Reverri, Elizabeth J., Devitt, Amy A., Kajzer, Janice A., Baggs, Geraldine E., Borschel, Marlene W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213476/
https://www.ncbi.nlm.nih.gov/pubmed/30241407
http://dx.doi.org/10.3390/nu10101346
_version_ 1783367780011081728
author Reverri, Elizabeth J.
Devitt, Amy A.
Kajzer, Janice A.
Baggs, Geraldine E.
Borschel, Marlene W.
author_facet Reverri, Elizabeth J.
Devitt, Amy A.
Kajzer, Janice A.
Baggs, Geraldine E.
Borschel, Marlene W.
author_sort Reverri, Elizabeth J.
collection PubMed
description Human milk oligosaccharides (HMOs) are the third most abundant solid component in human milk after lactose and lipids. Preclinical research has demonstrated that HMOs and specifically 2′-fucosyllactose (2′-FL) are more than a prebiotic and have multiple functions, including immune, gut, and cognition benefits. Previously, human milk has been the only source for significant levels of HMOs. The most abundant HMO in most mothers’ breast milk is 2′-FL. Recently, 2′-FL has been synthesized and shown to be structurally identical to the 2′-FL found in human milk. 2′-FL HMO is now available in some commercial infant formulas. The purpose of this narrative review was to summarize the clinical experiences of feeding infant formula supplemented with the HMO, 2′-FL. Most of these studies investigated standard intact milk protein-based infant formulas containing 2′-FL, and one evaluated a partially hydrolyzed whey-based formula. Collectively, these clinical experiences demonstrated that 2′-FL being added to infant formula was safe, well-tolerated, and absorbed and excreted with similar efficiency to 2′-FL in human milk. Further, infants that were fed formula with 2′-FL had immune benefits, fewer parent-reported respiratory infections, and improved symptoms of formula intolerance. Ultimately, infant formula with 2′-FL supports immune and gut health and is closer compositionally and functionally to human milk.
format Online
Article
Text
id pubmed-6213476
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62134762018-11-06 Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2′-Fucosyllactose Reverri, Elizabeth J. Devitt, Amy A. Kajzer, Janice A. Baggs, Geraldine E. Borschel, Marlene W. Nutrients Review Human milk oligosaccharides (HMOs) are the third most abundant solid component in human milk after lactose and lipids. Preclinical research has demonstrated that HMOs and specifically 2′-fucosyllactose (2′-FL) are more than a prebiotic and have multiple functions, including immune, gut, and cognition benefits. Previously, human milk has been the only source for significant levels of HMOs. The most abundant HMO in most mothers’ breast milk is 2′-FL. Recently, 2′-FL has been synthesized and shown to be structurally identical to the 2′-FL found in human milk. 2′-FL HMO is now available in some commercial infant formulas. The purpose of this narrative review was to summarize the clinical experiences of feeding infant formula supplemented with the HMO, 2′-FL. Most of these studies investigated standard intact milk protein-based infant formulas containing 2′-FL, and one evaluated a partially hydrolyzed whey-based formula. Collectively, these clinical experiences demonstrated that 2′-FL being added to infant formula was safe, well-tolerated, and absorbed and excreted with similar efficiency to 2′-FL in human milk. Further, infants that were fed formula with 2′-FL had immune benefits, fewer parent-reported respiratory infections, and improved symptoms of formula intolerance. Ultimately, infant formula with 2′-FL supports immune and gut health and is closer compositionally and functionally to human milk. MDPI 2018-09-21 /pmc/articles/PMC6213476/ /pubmed/30241407 http://dx.doi.org/10.3390/nu10101346 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Reverri, Elizabeth J.
Devitt, Amy A.
Kajzer, Janice A.
Baggs, Geraldine E.
Borschel, Marlene W.
Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2′-Fucosyllactose
title Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2′-Fucosyllactose
title_full Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2′-Fucosyllactose
title_fullStr Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2′-Fucosyllactose
title_full_unstemmed Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2′-Fucosyllactose
title_short Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2′-Fucosyllactose
title_sort review of the clinical experiences of feeding infants formula containing the human milk oligosaccharide 2′-fucosyllactose
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213476/
https://www.ncbi.nlm.nih.gov/pubmed/30241407
http://dx.doi.org/10.3390/nu10101346
work_keys_str_mv AT reverrielizabethj reviewoftheclinicalexperiencesoffeedinginfantsformulacontainingthehumanmilkoligosaccharide2fucosyllactose
AT devittamya reviewoftheclinicalexperiencesoffeedinginfantsformulacontainingthehumanmilkoligosaccharide2fucosyllactose
AT kajzerjanicea reviewoftheclinicalexperiencesoffeedinginfantsformulacontainingthehumanmilkoligosaccharide2fucosyllactose
AT baggsgeraldinee reviewoftheclinicalexperiencesoffeedinginfantsformulacontainingthehumanmilkoligosaccharide2fucosyllactose
AT borschelmarlenew reviewoftheclinicalexperiencesoffeedinginfantsformulacontainingthehumanmilkoligosaccharide2fucosyllactose